Stevanato Group (NYSE:STVN) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Stevanato Group S.p.A. (NYSE:STVN) saw an uptick in trading volume on Wednesday . 967,490 shares traded hands during trading, an increase of 176% from the previous session’s volume of 350,676 shares.The stock last traded at €20.64 ($21.50) and had previously closed at €20.91 ($21.78).

Wall Street Analyst Weigh In

STVN has been the subject of several analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Wolfe Research assumed coverage on shares of Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price target on the stock. Finally, Bank of America lifted their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy” and a consensus target price of €28.60 ($29.79).

Stevanato Group Stock Performance

The company has a market capitalization of $6.45 billion, a price-to-earnings ratio of 45.30, a P/E/G ratio of 7.45 and a beta of 0.56. The company has a 50 day moving average price of €21.57 and a 200 day moving average price of €20.49. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN) last issued its earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The firm had revenue of €277.90 million for the quarter, compared to analyst estimates of €274.36 million. During the same period in the previous year, the company earned $0.16 earnings per share. Stevanato Group’s revenue for the quarter was up 2.4% compared to the same quarter last year. Equities research analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stevanato Group

A number of institutional investors have recently added to or reduced their stakes in the company. Hardy Reed LLC increased its stake in shares of Stevanato Group by 8.2% during the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock worth $222,000 after purchasing an additional 840 shares during the last quarter. Lindenwold Advisors INC increased its position in Stevanato Group by 13.5% in the third quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock worth $239,000 after buying an additional 1,415 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of Stevanato Group by 12.7% during the 3rd quarter. Captrust Financial Advisors now owns 13,100 shares of the company’s stock valued at $262,000 after buying an additional 1,480 shares during the last quarter. Raymond James Trust N.A. grew its stake in shares of Stevanato Group by 22.6% during the 3rd quarter. Raymond James Trust N.A. now owns 12,556 shares of the company’s stock worth $251,000 after acquiring an additional 2,317 shares during the period. Finally, SG Americas Securities LLC increased its holdings in Stevanato Group by 18.2% in the 4th quarter. SG Americas Securities LLC now owns 15,546 shares of the company’s stock worth $339,000 after acquiring an additional 2,389 shares during the last quarter.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.